Why the study?
Do sodium-glucose co-transporter type 2 inhibitors reduce central blood pressure in type 2 diabetic patients with hypertension and nephropathy?
Do sodium-glucose co-transporter type 2 inhibitors reduce central blood pressure in type 2 diabetic patients with hypertension and nephropathy?
SGLT2 inhibitors demonstrate a class effect in reducing central blood pressure in patients with type 2 diabetes, hypertension, and nephropathy.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors may lower central BP in diabetic nephropathy; leaves open CV outcome impact.
AIMS: To assess the effects of sodium-glucose co-transporter type 2 inhibitors on central blood pressure, an important determinant of cardiovascular events. METHODS: Canagliflozin, Empagliflozin or Luseogliflozin was given for 102 type 2 diabetic patients with hypertension and nephropathy. Central blood pressure was evaluated by radial tonometry. Clinical parameters were followed for 6 months. RESULTS: Three differing sodium-glucose co-transporter type 2 inhibitors similarly reduced brachial and central blood pressures, casual blood sugar, haemoglobin A1c, estimated glomerular filtration rate and albuminuria without significant changes in pulse rate and lipid profiles. Central systolic blood pressure was associated with the decreases in albuminuria by sodium-glucose co-transporter type 2 inhibitors. CONCLUSION: Comparable influences of various sodium-glucose co-transporter type 2 inhibitors on central blood pressure suggest class effects.
No takes yet. Share an insight, caveat, or question.
Takenaka et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: